Revenue
2011
2012
2024
2025
TuHURA Biosciences, Inc./NV (HURA)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2024
2025
Financial statements
| 2025 | 2024 · Dec 31 | 2024 · Jun 30 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 · Dec 31 | 2011 · Jun 30 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | $0 | — | $0 |
| Research & development | $20.5M | $13.3M | $2.7M | $9.3M | $15.2M | $11.8M | $3.6M | $3.7M | — | $5.0M | $3.4M | $2.6M | — | $2.3M | — | $1.1M | — |
| Operating expenses | $31.8M | $17.6M | $8.5M | $14.8M | $22.7M | $38.2M | $9.2M | $8.4M | — | $8.3M | $6.2M | $4.7M | — | $6.3M | $18,885 | $1.3M | $33,136 |
| Operating income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | −$18,885 | — | −$33,136 |
| Net income | −$30.1M | −$21.7M | −$8.3M | −$14.6M | −$22.7M | −$38.3M | −$9.1M | −$8.0M | $11.1M | $8.1M | $8.9M | −$4.3M | $6.4M | −$8.3M | −$18,885 | −$1.3M | −$33,136 |
| Basic EPSper diluted share | -$0.63 | -$1.21 | -$0.32 | -$9.27 | -$25.80 | -$1.60 | -$0.87 | $3.16 | $5.42 | $0.74 | $0.83 | $0.46 | -$0.20 | -$0.28 | $0.00 | -$0.16 | $0.00 |
| Diluted EPSper diluted share | -$0.63 | -$1.21 | — | — | — | — | — | — | — | — | — | $0.11 | $0.00 | -$0.28 | $0.00 | -$0.16 | $0.00 |